Towards Healthcare
Residual DNA Testing Market Expands USD 328.48 Million in 2025

Residual DNA Testing Market 2025 North America Leads 49% with Shares

Based on market forecasts, the residual DNA testing sector will expand from USD 310 million in 2024 to USD 552.93 million by 2034, experiencing a CAGR of 5.96%. The residual DNA testing market is rising due to strict regulations to ensure patient safety. North America dominates the market due to the presence of strong regulatory organizations.

  • Insight Code: 5977
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The residual DNA testing market is worth USD 328.48 million in 2025, and by 2034, it is forecasted to hit USD 552.93 million, registering a CAGR of 5.96% over the decade.

North America is currently leading the residual DNA testing market due to the rising development of biologics.

The residual DNA testing market includes six segments such as by product & service, by technology, by end-user, by application, by sample type, and by region.

Some key players include Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), QIAGEN N.V., Roche Diagnostics, Promega Corporation, Agilent Technologies, Bio-Rad Laboratories, etc.

Less than 10 ng of DNA per therapeutic dosage (WHO) should be present in the finished product. According to a very sensitive procedure, the finished product should have the least amount of DNA feasible (FDA).

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.